Message from the Guest Editors

Dear Colleagues,

“Multidrug resistance” (MDR) cells are often simultaneously resistant to multiple stresses, such as radiotherapy, hypoxia, and nutrient shortages. Of note, MDR cells are also less recognized by the immune system, because they produce immune-suppressive metabolites and poorly raise an anti-tumor adaptive response by the host immune system in response to chemotherapy or radiotherapy. The reasons of this chemo-immune-resistance rely on the superior ability of MDR cells to adapt to stressing conditions. Metabolic rewiring and epigenetic events, such as the expression of specific miRNAs or ncRNAs, play a key role in such adaptation.

This Special Issue will focus on the latest studies dissecting the molecular linkages between chemoresistance and immune-resistance, and on new possible chemo-immune-sensitizer approaches, including radio-chemotherapy or radio-immune-chemo-therapy combinations, metabolic modifiers, and epigenetic modulators.

Dr. Chiara Riganti
Dr. Marialessandra Contino
Guest Editors